Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20967226 | 0.88 | LPL (0.42) | KDRLCKJAK3MAPK14LPL | |
| SCHEMBL24744297 | 0.82 | EGFR (0.43) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL31460801 | 0.82 | LPL (0.44) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL21047924 | 0.82 | LPL (0.44) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL7601177 | 0.80 | LPL (0.47) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL1368949 | 0.80 | EGFR (0.39) | LCKLPLLIPGSNCAIRAK4 | |
| SCHEMBL25403399 | 0.80 | IRAK4 (0.39) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL16880461 | 0.80 | SNCA (0.44) | LPLLIPGSNCAIRAK4EGFR | |
| SCHEMBL29545777 | 0.80 | EGFR (0.39) | LCKLPLLIPGSNCAIRAK4 | |
| SCHEMBL20292962 | 0.79 | EGFR (0.40) | KDRLPLLIPGSNCAIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| WO-2025076441-A1 | COMPOUNDS OF GCN2 MODULATORS | Alesta Therapeutics BV (NL) | 2025-04-10 | — | — | WO | disclosed |
| EP-4522610-A1 | GCN2 INHIBITORR | IP2IPO Innovations Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-115768750-A | GCN2 modulator compounds | 阿莱斯塔治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-2079724-B1 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| EP-2079724-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008011109-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | KDR 4504/4885LCK 4660/4885JAK3 4135/4885 |
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | KDR 4498/4885LCK 4310/4885JAK3 4665/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | KDR 4379/4885LCK 4271/4885JAK3 3787/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | KDR 370/4885LCK 323/4885JAK3 134/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | KDR 1044/4885LCK 106/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.